Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2017-10-31 16:02:31 UTC |
---|
Update Date | 2022-03-07 03:18:13 UTC |
---|
HMDB ID | HMDB0240206 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Bafetinib |
---|
Description | Bafetinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation of these cells in the blood. Bafetinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance. Notably, Bafetinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary. |
---|
Structure | CN(C)[C@H]1CCN(CC2=C(C=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CN=C3)=C(C)C=C2)C(F)(F)F)C1 InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1 |
---|
Synonyms | Value | Source |
---|
INNO-406 | MeSH | N-(3-((4,5'-Bipyrimidin)-2-ylamino)-4-methylphenyl)-4-(((3S)-3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide | MeSH | NS-187inno-406BAFETINIB | ChEMBL, HMDB |
|
---|
Chemical Formula | C30H31F3N8O |
---|
Average Molecular Weight | 576.6153 |
---|
Monoisotopic Molecular Weight | 576.257292269 |
---|
IUPAC Name | N-[3-({[4,5'-bipyrimidine]-2-yl}amino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide |
---|
Traditional Name | N-(3-{[4,5'-bipyrimidine]-2-ylamino}-4-methylphenyl)-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide |
---|
CAS Registry Number | 859212-16-1 |
---|
SMILES | CN(C)[C@H]1CCN(CC2=C(C=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CN=C3)=C(C)C=C2)C(F)(F)F)C1 |
---|
InChI Identifier | InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1 |
---|
InChI Key | ZGBAJMQHJDFTQJ-DEOSSOPVSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Anilides |
---|
Direct Parent | Benzanilides |
---|
Alternative Parents | |
---|
Substituents | - Benzanilide
- Bipyrimidine
- Trifluoromethylbenzene
- Benzamide
- Benzoic acid or derivatives
- Diaminotoluene
- Benzoyl
- Benzylamine
- Phenylmethylamine
- Aniline or substituted anilines
- Aralkylamine
- Toluene
- Aminopyrimidine
- N-alkylpyrrolidine
- Pyrimidine
- Pyrrolidine
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Secondary carboxylic acid amide
- Amino acid or derivatives
- Carboxamide group
- Organoheterocyclic compound
- Azacycle
- Carboxylic acid derivative
- Amine
- Organohalogen compound
- Organic oxide
- Alkyl halide
- Alkyl fluoride
- Organic oxygen compound
- Organic nitrogen compound
- Organofluoride
- Organonitrogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | Not Available |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Bafetinib,1TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C)C=C1NC1=NC=CC(C2=CN=CN=C2)=N1 | 4329.7 | Semi standard non polar | 33892256 | Bafetinib,1TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C)C=C1NC1=NC=CC(C2=CN=CN=C2)=N1 | 3877.4 | Standard non polar | 33892256 | Bafetinib,1TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C)C=C1NC1=NC=CC(C2=CN=CN=C2)=N1 | 5734.8 | Standard polar | 33892256 | Bafetinib,1TMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C | 4399.2 | Semi standard non polar | 33892256 | Bafetinib,1TMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C | 4097.6 | Standard non polar | 33892256 | Bafetinib,1TMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C | 5584.7 | Standard polar | 33892256 | Bafetinib,2TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C | 4181.0 | Semi standard non polar | 33892256 | Bafetinib,2TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C | 3843.0 | Standard non polar | 33892256 | Bafetinib,2TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C | 5208.1 | Standard polar | 33892256 | Bafetinib,1TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C(C)(C)C)C=C1NC1=NC=CC(C2=CN=CN=C2)=N1 | 4507.6 | Semi standard non polar | 33892256 | Bafetinib,1TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C(C)(C)C)C=C1NC1=NC=CC(C2=CN=CN=C2)=N1 | 4053.1 | Standard non polar | 33892256 | Bafetinib,1TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C(C)(C)C)C=C1NC1=NC=CC(C2=CN=CN=C2)=N1 | 5746.4 | Standard polar | 33892256 | Bafetinib,1TBDMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 4558.0 | Semi standard non polar | 33892256 | Bafetinib,1TBDMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 4265.0 | Standard non polar | 33892256 | Bafetinib,1TBDMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 5579.2 | Standard polar | 33892256 | Bafetinib,2TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C(C)(C)C)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 4498.4 | Semi standard non polar | 33892256 | Bafetinib,2TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C(C)(C)C)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 4176.5 | Standard non polar | 33892256 | Bafetinib,2TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CC[C@H](N(C)C)C3)C(C(F)(F)F)=C2)[Si](C)(C)C(C)(C)C)C=C1N(C1=NC=CC(C2=CN=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 5246.0 | Standard polar | 33892256 |
|
---|
| MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 10V, Positive-QTOF | splash10-004i-0040390000-e87c0acc07a42ddb443c | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 20V, Positive-QTOF | splash10-03g0-0390440000-52ebb49e5e879f1cfebd | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 40V, Positive-QTOF | splash10-01ri-2890100000-c2313e4460d8512f01cb | 2017-07-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 10V, Negative-QTOF | splash10-004i-0100090000-2c0d7c69c6c6f0ca547a | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 20V, Negative-QTOF | splash10-0200-3442290000-90d7133777a888520cb7 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 40V, Negative-QTOF | splash10-0100-9550010000-798bb3e96f2f8f62118f | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 10V, Positive-QTOF | splash10-004i-0000090000-962a71e30e420965bb57 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 20V, Positive-QTOF | splash10-03fr-0810290000-c263f269687456bf7f48 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 40V, Positive-QTOF | splash10-000i-4930150000-7ddeaa97cc30f1654a0d | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 10V, Negative-QTOF | splash10-004i-0000090000-85853253a5e2c3faaac8 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 20V, Negative-QTOF | splash10-004i-0000390000-e4f8bbfc295433ff8c43 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Bafetinib 40V, Negative-QTOF | splash10-00di-0020980000-6caa32826aac550f9eec | 2021-09-23 | Wishart Lab | View Spectrum |
|
---|